Comparison of oral toxicological properties of botulinum neurotoxin serotypes A and B

Toxicon

Volumn 58, Issue 1, 2011, Pages 62-67

  Cheng, Luisa W ^a   Henderson, Thomas D ^a  

^a WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

Bioavailability; Botulinum neurotoxins; Clostridium botulinum; Food matrices; Neurotoxin associated proteins (NAPs)

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROTOXIN; NEUROTOXIN ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BOTULISM; COMPARATIVE STUDY; CONTROLLED STUDY; EGG; FOOD POISONING; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK ASSESSMENT; TOXICOKINETICS; TOXIN ANALYSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; TOXICITY TESTS;

CLOSTRIDIUM BOTULINUM; MUS;

EID: 79959379300     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.05.003     Document Type: Article

References (30)

1. Ahsan C.R., Hajnoczky G., Maksymowych A.B., Simpson L.L. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 2005, 315(3):1028-1035.
2. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285(8):1059-1070.
3. Bigalke H., Rummel A. Medical aspects of toxin weapons. Toxicology 2005, 214(3):210-220.
4. Chen F., Kuziemko G.M., Stevens R.C. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun. 1998, 66(6):2420-2425.
5. Cheng L.W., Onisko B., Johnson E.A., Reader J.R., Griffey S.M., Larson A.E., Tepp W.H., Stanker L.H., Brandon D.L., Carter J.M. Effects of purification on the bioavailability of botulinum neurotoxin type A. Toxicology 2008, 249(2-3):123-129.
6. DasGupta B.R., Sugiyama H. Inhibition of Clostridium botulinum types A and B hemagglutinins by sugars. Can. J. Microbiol. 1977, 23(9):1257-1260.
7. Eisele K.H., Fink K., Vey M., Taylor H.V. Studies on the dissociation of botulinum neurtoxin type A complexes. Toxicon 2011, 57(4):555-565.
8. Fujinaga Y. Interaction of botulinum toxin with the epithelial barrier. J. Biomed. Biotechnol. 2010, 974943.
9. Fujinaga Y., Matsumura T., Jin Y., Takegahara Y., Sugawara Y. A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption. Toxicon 2009, 54(5):583-586.
10. Hasegawa K., Watanabe T., Suzuki T., Yamano A., Oikawa T., Sato Y., Kouguchi H., Yoneyama T., Niwa K., Ikeda T., Ohyama T. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J. Biol. Chem. 2007, 282(34):24777-24783.
11. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., Brown J.L., Johnson E.A., Smith L.A., Okinaka R.T., Jackson P.J., Marks J.D. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 2007, 189(3):818-832.
12. Hill K.K., Xie G., Foley B.T., Smith T.J., Munk A.C., Bruce D., Smith L.A., Brettin T.S., Detter J.C. Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains. BMC Biol. 2009, 7:66.
13. Hines H.B., Lebeda F., Hale M., Brueggemann E.E. Characterization of botulinum progenitor toxins by mass spectrometry. Appl. Environ. Microbiol. 2005, 71(8):4478-4486.
14. Inoue K., Fujinaga Y., Watanabe T., Ohyama T., Takeshi K., Moriishi K., Nakajima H., Inoue K., Oguma K. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. 1996, 64(5):1589-1594.
15. Jin Y., Takegahara Y., Sugawara Y., Matsumura T., Fujinaga Y. Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology 2009, 155(Pt 1):35-45.
16. Maksymowych A.B., Simpson L.L. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J.Biol. Chem. 1998, 273(34):21950-21957.
17. Maksymowych A.B., Simpson L.L. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 2004, 310(2):633-641.
18. Matsumura T., Jin Y., Kabumoto Y., Takegahara Y., Oguma K., Lencer W.I., Fujinaga Y. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell Microbiol. 2008, 10(2):355-364.
19. Nakamura T., Takada N., Tonozuka T., Sakano Y., Oguma K., Nishikawa A. Binding properties of Clostridium botulinum type C progenitor toxin to mucins. Biochim. Biophys. Acta 2007, 1770(4):551-555.
20. Niwa K., Koyama K., Inoue S., Suzuki T., Hasegawa K., Watanabe T., Ikeda T., Ohyama T. Role of nontoxic components of serotype D botulinum toxin complex in permeation through a Caco-2 cell monolayer, a model for intestinal epithelium. FEMS Immunol. Med. Microbiol. 2007, 49(3):346-352.
21. Ohishi I. Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect. Immun. 1984, 43(2):487-490.
22. Ohishi I., Sugii S., Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect. Immun. 1977, 16(1):107-109.
23. Rasetti-Escargueil C., Jones R.G., Liu Y., Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009, 53(5):503-511.
24. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493.
25. Scarlatos A., Welt B.A., Cooper B.Y., Archer D., DeMarse T., Chau K.V. Methods for detecting botulinum toxin with applicability to screening foods against biological terrorist attacks. J. Food Sci. 2005, 70(8):121-130.
26. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
27. Smith T.J., Hill K.K., Foley B.T., Detter J.C., Munk A.C., Bruce D.C., Doggett N.A., Smith L.A., Marks J.D., Xie G., Brettin T.S. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3,/Ba4 and/B1 clusters are located within plasmids. PLoS One 2007, 2(12):e1271.
28. Sugii S., Ohishi I., Sakaguchi G. Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect. Immun. 1977, 16(3):910-914.
29. Weil C.S. Tables for the convenient calculation of median-effective dose (LD50 or ED50) and instructions in their use. Biometrics 1952, 8:249-263.
30. Zhou Y., Foss S., Lindo P., Sarkar H., Singh B.R. Hemagglutinin-33 of type A botulinum neurotoxin complex binds with synaptotagmin II. FEBS J. 2005, 272(11):2717-2726.